Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
35.51
+0.41 (1.17%)
At close: Aug 1, 2025, 4:00 PM
35.51
0.00 (-0.01%)
After-hours: Aug 1, 2025, 4:04 PM EDT

Company Description

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States.

The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.

It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea.

In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS.

It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors.

It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820.

Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals logo
CountryUnited States
Founded2005
IPO DateMay 1, 2012
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees674
CEOJack Khattar

Contact Details

Address:
9715 Key West Avenue
Rockville, Maryland 20850
United States
Phone301 838 2500
Websitesupernus.com

Stock Details

Ticker SymbolSUPN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001356576
CUSIP Number868459108
ISIN NumberUS8684591089
SIC Code2834

Key Executives

NamePosition
Jack A. Khattar M.B.A.Founder, President, Chief Executive Officer, Secretary and Director
Timothy C. DecSenior Vice President and Chief Financial Officer
Dr. Padmanabh P. Bhatt Ph.D.Chief Scientific Officer and Senior Vice President of Intellectual Property
Dr. Jonathan Rubin M.B.A., M.D.Senior Vice President of Research and Development and Chief Medical Officer
Kevin T. Anderson Esq.Compliance Officer
Dr. Todd Horich M.B.A., Ph.D.Senior Vice President of Marketing, Commercial Operations and Market Access
Taylor RaifordSenior Vice President of Sales
Dr. Bryan A. Roecklein Ph.D.Senior Vice President of Corporate Development
Jeff BozickSenior Vice President of Supply Chain

Latest SEC Filings

DateTypeTitle
Jul 31, 20258-KCurrent Report
Jul 22, 20258-KCurrent Report
Jun 17, 20258-KCurrent Report
Jun 16, 20258-KCurrent Report
May 28, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 6, 202510-QQuarterly Report
May 6, 20258-KCurrent Report
Apr 30, 2025ARSFiling
Apr 30, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material